Legal challenges put off label use of gender affirming care drugs in jeopardy

2023-03-16

上市批准

Legal challenges put off label use of gender affirming care drugs in jeopardy

Preview

来源: Pharmaceutical Technology

Credit: Shutterstock/ Chaos810

Earlier this week, the Florida Senate advanced a bill to restrict gender-affirming care for transgender minors. The bill is one of many that are currently being discussed in different states.

Free Report

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Access the report to:

Benchmark the impact of major themes on the Biopharmaceutical industry.

Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.

Evaluate the effects of COVID-19 on the sector.

Download the full report to understand what to expect and how to align your strategies for success.

By GlobalData

Preview

来源: Pharmaceutical Technology

Submit

Country Code

UK (+44)

USA (+1)

Algeria (+213)

Andorra (+376)

Angola (+244)

Anguilla (+1264)

Antigua & Barbuda (+1268)

Argentina (+54)

Armenia (+374)

Aruba (+297)

Australia (+61)

Austria (+43)

Azerbaijan (+994)

Bahamas (+1242)

Bahrain (+973)

Bangladesh (+880)

Barbados (+1246)

Belarus (+375)

Belgium (+32)

Belize (+501)

Benin (+229)

Bermuda (+1441)

Bhutan (+975)

Bolivia (+591)

Bosnia Herzegovina (+387)

Botswana (+267)

Brazil (+55)

Brunei (+673)

Bulgaria (+359)

Burkina Faso (+226)

Burundi (+257)

Cambodia (+855)

Cameroon (+237)

Canada (+1)

Cape Verde Islands (+238)

Cayman Islands (+1345)

Central African Republic (+236)

Chile (+56)

China (+86)

Colombia (+57)

Comoros (+269)

Congo (+242)

Cook Islands (+682)

Costa Rica (+506)

Croatia (+385)

Cuba (+53)

Cyprus North (+90392)

Cyprus South (+357)

Czech Republic (+42)

Denmark (+45)

Djibouti (+253)

Dominica (+1809)

Dominican Republic (+1809)

Ecuador (+593)

Egypt (+20)

El Salvador (+503)

Equatorial Guinea (+240)

Eritrea (+291)

Estonia (+372)

Ethiopia (+251)

Falkland Islands (+500)

Faroe Islands (+298)

Fiji (+679)

Finland (+358)

France (+33)

French Guiana (+594)

French Polynesia (+689)

Gabon (+241)

Gambia (+220)

Georgia (+7880)

Germany (+49)

Ghana (+233)

Gibraltar (+350)

Greece (+30)

Greenland (+299)

Grenada (+1473)

Guadeloupe (+590)

Guam (+671)

Guatemala (+502)

Guinea (+224)

Guinea - Bissau (+245)

Guyana (+592)

Haiti (+509)

Honduras (+504)

Hong Kong (+852)

Hungary (+36)

Iceland (+354)

India (+91)

Indonesia (+62)

Iran (+98)

Iraq (+964)

Ireland (+353)

Israel (+972)

Italy (+39)

Jamaica (+1876)

Japan (+81)

Jordan (+962)

Kazakhstan (+7)

Kenya (+254)

Kiribati (+686)

Korea North (+850)

Korea South (+82)

Kuwait (+965)

Kyrgyzstan (+996)

Laos (+856)

Latvia (+371)

Lebanon (+961)

Lesotho (+266)

Liberia (+231)

Libya (+218)

Liechtenstein (+417)

Lithuania (+370)

Luxembourg (+352)

Macao (+853)

Macedonia (+389)

Madagascar (+261)

Malawi (+265)

Malaysia (+60)

Maldives (+960)

Mali (+223)

Malta (+356)

Marshall Islands (+692)

Martinique (+596)

Mauritania (+222)

Mayotte (+269)

Mexico (+52)

Micronesia (+691)

Moldova (+373)

Monaco (+377)

Mongolia (+976)

Montserrat (+1664)

Morocco (+212)

Mozambique (+258)

Myanmar (+95)

Namibia (+264)

Nauru (+674)

Nepal (+977)

Netherlands (+31)

New Caledonia (+687)

New Zealand (+64)

Nicaragua (+505)

Niger (+227)

Nigeria (+234)

Niue (+683)

Norfolk Islands (+672)

Northern Marianas (+670)

Norway (+47)

Oman (+968)

Palau (+680)

Panama (+507)

Papua New Guinea (+675)

Paraguay (+595)

Peru (+51)

Philippines (+63)

Poland (+48)

Portugal (+351)

Puerto Rico (+1787)

Qatar (+974)

Reunion (+262)

Romania (+40)

Russia (+7)

Rwanda (+250)

San Marino (+378)

Sao Tome & Principe (+239)

Saudi Arabia (+966)

Senegal (+221)

Serbia (+381)

Seychelles (+248)

Sierra Leone (+232)

Singapore (+65)

Slovak Republic (+421)

Slovenia (+386)

Solomon Islands (+677)

Somalia (+252)

South Africa (+27)

Spain (+34)

Sri Lanka (+94)

St. Helena (+290)

St. Kitts (+1869)

St. Lucia (+1758)

Sudan (+249)

Suriname (+597)

Swaziland (+268)

Sweden (+46)

Switzerland (+41)

Syria (+963)

Taiwan (+886)

Tajikstan (+7)

Thailand (+66)

Togo (+228)

Tonga (+676)

Trinidad & Tobago (+1868)

Tunisia (+216)

Turkey (+90)

Turkmenistan (+7)

Turkmenistan (+993)

Turks & Caicos Islands (+1649)

Tuvalu (+688)

Uganda (+256)

UK (+44) -->

Ukraine (+380)

United Arab Emirates (+971)

Uruguay (+598)

USA (+1) -->

Uzbekistan (+7)

Vanuatu (+678)

Vatican City (+379)

Venezuela (+58)

Vietnam (+84)

Virgin Islands - British (+1284)

Virgin Islands - US (+1340)

Wallis & Futuna (+681)

Yemen (North)(+969)

Yemen (South)(+967)

Zambia (+260)

Zimbabwe (+263)

Country

USA

Afghanistan

Åland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua and Barbuda

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bonaire, Sint Eustatius and Saba

Bosnia and Herzegovina

Botswana

Bouvet Island

Brazil

British Indian Ocean Territory

Brunei Darussalam

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Cape Verde

Cayman Islands

Central African Republic

Chad

Chile

China

Christmas Island

Cocos Islands

Colombia

Comoros

Congo

Democratic Republic of

the Congo

Cook Islands

Costa Rica

Côte d"Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czech Republic

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

France

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Germany

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Heard Island and McDonald Islands

Holy See

Honduras

Hong Kong

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Isle of Man

Israel

Italy

Jamaica

Japan

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

North Korea

South Korea

Kuwait

Kyrgyzstan

Lao

Latvia

Lebanon

Lesotho

Liberia

Libyan Arab Jamahiriya

Liechtenstein

Lithuania

Luxembourg

Macao

Macedonia, The Former

Yugoslav Republic of

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Netherlands

New Caledonia

New Zealand

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territory

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Russian Federation

Rwanda

Saint Helena, Ascension and Tristan da Cunha

Saint Kitts and Nevis

Saint Lucia

Saint Pierre and Miquelon

Saint Vincent and The Grenadines

Samoa

San Marino

Sao Tome and Principe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia and The South

Sandwich Islands

Spain

Sri Lanka

Sudan

Suriname

Svalbard and Jan Mayen

Swaziland

Sweden

Switzerland

Syrian Arab Republic

Taiwan

Tajikistan

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad and Tobago

Tunisia

Turkey

Turkmenistan

Turks and Caicos Islands

Tuvalu

Uganda

Ukraine

United Arab Emirates

US Minor Outlying Islands

Uruguay

Uzbekistan

Vanuatu

Venezuela

Vietnam

British Virgin Islands

US Virgin Islands

Wallis and Futuna

Western Sahara

Yemen

Zambia

Zimbabwe

Kosovo

-->

--> Submit

By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy

By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you.

Please check your email to download the Report.

Many politicians have cited doubts about the potential “harm” caused by puberty blockers and hormone therapies associated with gender-affirming care and concerns about incorrect treatment as major factors. However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. Dr. Barry DeCoster, PhD, an associate professor of bioethics at the University of Michigan, describes gender affirming care as “safe and effective” for most patients. Most drugs used here are prescribed off-label, and experts say pharmaceutical companies remain hesitant to conduct clinical trials studying gender-affirming care. This has pushed clinicians to explore different routes to prove the validity of these drugs.

The World Health Organization (WHO) defines gender-affirming care as a range of social, psychological, behavioural, and medical interventions that are “designed to support and affirm an individual’s gender identity” when it conflicts with the gender they were assigned at birth.

The laws proposed in several bills range in their potential influence; from restricting the prescription of gender-affirming drugs to criminalising the use of such drugs to allowing states to pursue lawsuits against parents who allow children to access such treatments. Dr Lisa Campo-Engelstein, a bioethicist, predicts that these factors and subsequent restrictions on statewide healthcare coverage will heavily restrict patient access to gender-affirming care. Campo-Engelstein is the director of the Institute for Bioethics & Health Humanities at the University of Texas Medical Branch, Galveston.

With restricted access and reduced prescription of puberty blockers and hormone therapies, the impact on pharmaceutical companies manufacturing these therapies also remains unclear.

Standards of care for gender-affirming therapies

The global standards for gender-affirming medical practices stem from the World Professional Association for Transgender Health (WPATH)’s yearly guidelines. WPATH’s recommendations are based on “the best available science and expert professional consensus” to give “safe and effective pathways” for transsexual, transgender, and gender-nonconforming people.

WPATH suggests an individualised approach to treating gender dysphoria. Generally, individuals first take on social gender-affirmation changes. Dr Sean Cahill, PhD, the associate editor of the global, peer-reviewed journal LGBT Health, says “for most young people, healthcare provided doesn’t even go beyond that [social affirmation of gender identity], but a lot of people… are misrepresenting what gender affirming care looks like in this country”. Following this, they may progress to the use of puberty blockers. After a minor has been on puberty blockers for two to three years, they may have the option to use hormone therapies upon further evaluation.

Puberty blockers are used in gender affirming care to delay the onset of puberty for gender dysphoric children of any gender. These drugs do not tend to have permanent effects and only cause a pause in puberty. While hormone therapies are allowed in the US, the age limit for this is dependent on the geographical area. Standard puberty blockers include Gonadotrophin Releasing Hormone (GnRH) analogues like Trelstar (triptorelin), Supprelin (Histrelin), and Zoladex (Goserelin), are only prescribed off label in the US and UK for gender affirming care. For example, Ontario, Canada-based Verity Pharmaceuticals’s Trelstar was FDA approved for palliative treatment of advanced prostate cancer and the other two are indicated for treating central precocious puberty and endometriosis, respectively. Several companies that produce commonly used puberty blockers such as Vantas Pharmaceuticals, Endo International and TerSera Therapeutics, have remained silent on the ongoing debate.

Additionally, hormone therapies—testosterone to “masculinise” and/or transition to men, and oestrogen for transitioning to women and/or “feminising” the body—are an integral part of the plan. Testosterone stops menstrual cycles, decreases the ovaries’ ability to make oestrogen and more, while oestrogen allows individuals to develop breasts, rounder hips and changes to the reproductive system. The most commonly used testosterones in the US include Endo International’s Delatestryl (testosterone enanthate) and Aveed (testosterone undecanoate), and Pfizer’s Depo-testosterone (testosterone cypionate). These changes can be irreversible and can take up to five years to reach maximum effect. Common oestrogen therapies are mostly oestradiols such as Novartis’ Vivelle-Dot, Ascend Therapeutics’ Estrogel, and Teva Pharmaceuticals’ Gynodiol. Oestrogen hormone therapies are often approved for restoring hormone levels for cisgendered women, to reduce symptoms such as hot flushes and vaginal dryness.

Dr. Edmund Horowicz PhD, a lecturer in medical law and ethics at the University of Liverpool, counters discourse from those such as the Norwegian Healthcare Investigation Board UKOM, that characterises puberty blockers as “experimental” and untrustworthy due to their off-label prescription. One of the reasons why organisations, including pharma companies, do not enter this debate is because these drugs are used off label, says Horowicz. As these drugs are not licensed for the specific indication of gender-affirming care, collecting safety data on off-label use is not viewed as a priority.

Cahill says health centers across the nation, like his, see a sizable transgender population, and would be able to easily conduct longitudinal drug studies investigating safety measures and patient satisfaction. But the funding is not there, he adds. The onus for funding would most likely be on government agencies like the National Institutes of Health (NIH), says Cahill.

Moreover, there are some logistical barriers in designing such studies. While it is important to run randomised placebo-controlled trials, giving participants sham gender affirming care, for example, would worsen mental distress associated with gender dysphoria, says Horowicz. There might also be ethical considerations for denying care and some subjects may also drop out of studies.

Still, while the long-term impact of puberty blockers on bone-density and muscular skeletal development still needs to be studied, Horowicz asserts this should be viewed as a risk associated with a drug, similar to all other drugs. In Georgia’s bill, the legislators reason that the bill would be necessary under the “do no harm” principle, expressing safety concerns for minors.

Due to a lack of long-term data into the possible impacts of these drugs, some people have proposed a possible solution of only prescribing these drugs within studies until more data arises. But this would restrict these drugs to only those who choose to be trial participants, creating further ethical conundrums, says Horowicz. Furthermore, Horowicz states that clinical frameworks, such as WPATH’s guidelines, are already based on evidence from trials of these well-established drugs. New studies for this use would be “more to satisfy those who are concerned about the provision of puberty blockers than any kind of traditional expected model of pharmacological research”.

Possible consequences

Last year, the Biden administration proposed the implementation of a rule in section 1557, that would protect against limiting access to care by stating that “categorically refusing to provide treatment to an individual based on their gender identity is prohibited discrimination”. However, the recent state-specific gender affirmation legislations may look to contradict this. For example, in Florida, the Agency for Health Care Administration has prohibited Medicaid from covering any kind of gender-affirming care procedures like hormone therapies.

Campo-Engelstein says some states like Texas don’t allow coverage for gender-affirming care through public systems. However, she points out that gender affirmation practices are still completely legal in the context of intersex “correction”, yet lawmakers contradict their use for transgender individuals.

An immediate consequence of the possible legal ramifications of the bills is a shift in patient care and healthcare coverage, particularly for publicly funded hospitals. A bellwether for which states may see major changes in drug prescription and coverage, may be the ones that saw changes in access to abortion following the Supreme Court overturning Roe v Wade. “States that are banning abortion are going to be more likely to ban gender affirming care, because they’re both motivated by the same social and political values,” says Campo-Engelstein.

DeCoster says the lack of consultation with clinicians and patients in deciding these legislations does a disservice to those most affected by the new laws. “We should be having a health care system that is helping support and to raise up people to give them what they need,” he says.

Free Report

How is the Biopharmaceutical industry evolving?

Access the report to:

Benchmark the impact of major themes on the Biopharmaceutical industry.

Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.

Evaluate the effects of COVID-19 on the sector.

Download the full report to understand what to expect and how to align your strategies for success.

By GlobalData

Preview

来源: Pharmaceutical Technology

Submit

Country Code

UK (+44)

USA (+1)

Algeria (+213)

Andorra (+376)

Angola (+244)

Anguilla (+1264)

Antigua & Barbuda (+1268)

Argentina (+54)

Armenia (+374)

Aruba (+297)

Australia (+61)

Austria (+43)

Azerbaijan (+994)

Bahamas (+1242)

Bahrain (+973)

Bangladesh (+880)

Barbados (+1246)

Belarus (+375)

Belgium (+32)

Belize (+501)

Benin (+229)

Bermuda (+1441)

Bhutan (+975)

Bolivia (+591)

Bosnia Herzegovina (+387)

Botswana (+267)

Brazil (+55)

Brunei (+673)

Bulgaria (+359)

Burkina Faso (+226)

Burundi (+257)

Cambodia (+855)

Cameroon (+237)

Canada (+1)

Cape Verde Islands (+238)

Cayman Islands (+1345)

Central African Republic (+236)

Chile (+56)

China (+86)

Colombia (+57)

Comoros (+269)

Congo (+242)

Cook Islands (+682)

Costa Rica (+506)

Croatia (+385)

Cuba (+53)

Cyprus North (+90392)

Cyprus South (+357)

Czech Republic (+42)

Denmark (+45)

Djibouti (+253)

Dominica (+1809)

Dominican Republic (+1809)

Ecuador (+593)

Egypt (+20)

El Salvador (+503)

Equatorial Guinea (+240)

Eritrea (+291)

Estonia (+372)

Ethiopia (+251)

Falkland Islands (+500)

Faroe Islands (+298)

Fiji (+679)

Finland (+358)

France (+33)

French Guiana (+594)

French Polynesia (+689)

Gabon (+241)

Gambia (+220)

Georgia (+7880)

Germany (+49)

Ghana (+233)

Gibraltar (+350)

Greece (+30)

Greenland (+299)

Grenada (+1473)

Guadeloupe (+590)

Guam (+671)

Guatemala (+502)

Guinea (+224)

Guinea - Bissau (+245)

Guyana (+592)

Haiti (+509)

Honduras (+504)

Hong Kong (+852)

Hungary (+36)

Iceland (+354)

India (+91)

Indonesia (+62)

Iran (+98)

Iraq (+964)

Ireland (+353)

Israel (+972)

Italy (+39)

Jamaica (+1876)

Japan (+81)

Jordan (+962)

Kazakhstan (+7)

Kenya (+254)

Kiribati (+686)

Korea North (+850)

Korea South (+82)

Kuwait (+965)

Kyrgyzstan (+996)

Laos (+856)

Latvia (+371)

Lebanon (+961)

Lesotho (+266)

Liberia (+231)

Libya (+218)

Liechtenstein (+417)

Lithuania (+370)

Luxembourg (+352)

Macao (+853)

Macedonia (+389)

Madagascar (+261)

Malawi (+265)

Malaysia (+60)

Maldives (+960)

Mali (+223)

Malta (+356)

Marshall Islands (+692)

Martinique (+596)

Mauritania (+222)

Mayotte (+269)

Mexico (+52)

Micronesia (+691)

Moldova (+373)

Monaco (+377)

Mongolia (+976)

Montserrat (+1664)

Morocco (+212)

Mozambique (+258)

Myanmar (+95)

Namibia (+264)

Nauru (+674)

Nepal (+977)

Netherlands (+31)

New Caledonia (+687)

New Zealand (+64)

Nicaragua (+505)

Niger (+227)

Nigeria (+234)

Niue (+683)

Norfolk Islands (+672)

Northern Marianas (+670)

Norway (+47)

Oman (+968)

Palau (+680)

Panama (+507)

Papua New Guinea (+675)

Paraguay (+595)

Peru (+51)

Philippines (+63)

Poland (+48)

Portugal (+351)

Puerto Rico (+1787)

Qatar (+974)

Reunion (+262)

Romania (+40)

Russia (+7)

Rwanda (+250)

San Marino (+378)

Sao Tome & Principe (+239)

Saudi Arabia (+966)

Senegal (+221)

Serbia (+381)

Seychelles (+248)

Sierra Leone (+232)

Singapore (+65)

Slovak Republic (+421)

Slovenia (+386)

Solomon Islands (+677)

Somalia (+252)

South Africa (+27)

Spain (+34)

Sri Lanka (+94)

St. Helena (+290)

St. Kitts (+1869)

St. Lucia (+1758)

Sudan (+249)

Suriname (+597)

Swaziland (+268)

Sweden (+46)

Switzerland (+41)

Syria (+963)

Taiwan (+886)

Tajikstan (+7)

Thailand (+66)

Togo (+228)

Tonga (+676)

Trinidad & Tobago (+1868)

Tunisia (+216)

Turkey (+90)

Turkmenistan (+7)

Turkmenistan (+993)

Turks & Caicos Islands (+1649)

Tuvalu (+688)

Uganda (+256)

UK (+44) -->

Ukraine (+380)

United Arab Emirates (+971)

Uruguay (+598)

USA (+1) -->

Uzbekistan (+7)

Vanuatu (+678)

Vatican City (+379)

Venezuela (+58)

Vietnam (+84)

Virgin Islands - British (+1284)

Virgin Islands - US (+1340)

Wallis & Futuna (+681)

Yemen (North)(+969)

Yemen (South)(+967)

Zambia (+260)

Zimbabwe (+263)

Country

USA

Afghanistan

Åland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua and Barbuda

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bonaire, Sint Eustatius and Saba

Bosnia and Herzegovina

Botswana

Bouvet Island

Brazil

British Indian Ocean Territory

Brunei Darussalam

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Cape Verde

Cayman Islands

Central African Republic

Chad

Chile

China

Christmas Island

Cocos Islands

Colombia

Comoros

Congo

Democratic Republic of

the Congo

Cook Islands

Costa Rica

Côte d"Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czech Republic

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

France

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Germany

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Heard Island and McDonald Islands

Holy See

Honduras

Hong Kong

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Isle of Man

Israel

Italy

Jamaica

Japan

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

North Korea

South Korea

Kuwait

Kyrgyzstan

Lao

Latvia

Lebanon

Lesotho

Liberia

Libyan Arab Jamahiriya

Liechtenstein

Lithuania

Luxembourg

Macao

Macedonia, The Former

Yugoslav Republic of

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Netherlands

New Caledonia

New Zealand

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territory

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Russian Federation

Rwanda

Saint Helena, Ascension and Tristan da Cunha

Saint Kitts and Nevis

Saint Lucia

Saint Pierre and Miquelon

Saint Vincent and The Grenadines

Samoa

San Marino

Sao Tome and Principe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia and The South

Sandwich Islands

Spain

Sri Lanka

Sudan

Suriname

Svalbard and Jan Mayen

Swaziland

Sweden

Switzerland

Syrian Arab Republic

Taiwan

Tajikistan

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad and Tobago

Tunisia

Turkey

Turkmenistan

Turks and Caicos Islands

Tuvalu

Uganda

Ukraine

United Arab Emirates

US Minor Outlying Islands

Uruguay

Uzbekistan

Vanuatu

Venezuela

Vietnam

British Virgin Islands

US Virgin Islands

Wallis and Futuna

Western Sahara

Yemen

Zambia

Zimbabwe

Kosovo

-->

--> Submit

By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy

By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Thank you.

Please check your email to download the Report.